An interventional study of Initial standardized global review in Axial Spondylarthritis (axSpA), sponsored by Association de Recherche Clinique en Rhumatologie. Recruiting at 21 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Association de Recherche Clinique en Rhumatologie · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.
Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 39th registered.
187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
Browse Axial Spondyloarthritis studies →9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 13 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 154 is above the median of 106 across 123 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 188 across the 30 interventional studies, 413 across the 10 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Association de Recherche Clinique en Rhumatologie is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Association de Recherche Clinique en Rhumatologie has 3 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654753Phase 3Assistance Publique - Hôpitaux de ParisThe Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment | 2027-09 |
| NCT06259890Centre Hospitalier Universitaire de BesanconInfluence of Sodium Intake in spondyLoarthriTes | 2026-11 |
| NCT04286373Assistance Publique - Hôpitaux de ParisEfficacy of Non-invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies | 2026-12 |
| NCT07141017Association de Recherche Clinique en RhumatologieInitial Standardized Global Review in Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Axial Spondyloarthritis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be a pragmatic, cluster-randomized, controlled study with two parallel arms ( 'intervention' and 'usual care' (UC) arms) of one year duration.
The study will be open-label, but centers randomized in the UC arm will not be aware of the intervention performed in the 'intervention' centers.
The primary objective of this study will be to determine whether participation in a standardized global review (that includes assessment of disease domains and education ) as soon as possible after diagnosis of axial spondyloarthritis has a beneficial impact on patient knowledge of the disease at 12 months. The primary endpoint will be the change in the SPAKE (SPondyloArthritis Knowledge Questionnaire) questionnaire between M0 and M12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Initial standardized global review
The intervention under study will be the initial standardized global review, which will be performed as soon as axial spondyloarthritis is diagnosed (less than 12 months from diagnosis is mandatory) and only at the baseline visit. This review includes both the assessment of different domains of the disease, but also the education and information on such different domains of the disease and its management The domains assessed during the intervention will be: diagnosis of spondyloarthritis, spondyloarthritis phenotype, disease activity, disease severity and function, treatment adherence and comorbidities. At the end of the intervention, a detailed medical report on this initial standardized global review will be produced and sent to the patient, their rheumatologist, their general practitioner, and their dispensing pharmacist.
The change in patient knowledge of the disease.
The primary endpoint will be the change in the SPAKE questionnaire
Time frame: Visits Day 0 and Month 12
Treatment
Treatment in both groups will be evaluated NSAID intake and % of patients receiving csDMARD/bDMARD/tsDMARD
Time frame: Visits Day 0 and Month 12
The ability to cope with the disease
The ability to cope with the disease will be evaluated by disease coping change between Day 0 and Month 12 in both groups using the Coping Scale from the RAID questionnaire
Time frame: Visits Day 0 and Month 12
Knowledge on b/tsDMARDs
Knowledge on b/tsDMARDs, only in patients with b/tsDMARD, will be evaluated by the BioSECURE'21 questionnaire
Time frame: Visits Day 0 and Month 12
Adherence to axSpA treatments
Adherence to axSpA treatments in both groups will be evaluated by the CQR5 questionnaire
Time frame: Visits Day 0 and Month 12
Disease activity
Disease activity will be evaluated by the disease activity score (ASDAS) change in both groups
Time frame: Visits Day 0 and Month 12
Number of comorbidities
Number of comorbidities managed according to recommendations in both groups
Time frame: Visit Month 12
Function change
Function change in both groups between will be evaluated by the BASFI questionnaire
Time frame: Visits Day 0 and Month 12
Quality of life change
Quality of life change in both groups will be evaluated by the ASAS-HI questionnaire
Time frame: Visits Day 0 and Month 12
Work impairment
Work impairment will be evaluated by the WPAI questionnaire
Time frame: Visit Month 12
Assessment of health services resources use
Assessment of health services resources use will be evaluated by self-questionnaire
Time frame: Visit Month 12
The patient's perception of the benefits of this type of initial global standardized review on patient's follow-up and the treating rheumatologist's perception of the benefits of this type of initial global standardized review on patient follow-up
The patient's perception of the benefits of this type of initial global standardized review on patient's follow-up and the treating rheumatologist's perception of the benefits of this type of initial global standardized review on patient follow-up will be evaluated by the Likert scale
Time frame: Visit Month 12
The sources of information accessed by patients
The sources of information accessed by patients in both groups be evaluated with the percentage of patients who participated in a therapeutic education programme
Time frame: Visits Day 0 and Month 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 24 months is below that.
Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association de Recherche Clinique en Rhumatologie